Information on the mutation status of NPM1, FLT3, and CEBPA was incomplete; however, 1 sample was known to be CEBPAdouble-mutant, and 2 samples were NPM1pos/FLT3-ITDneg, and were considered as favorable-risk AML specimens in subset analyses. This evidence concerns the gene FLT3 and acute myeloid leukemia.